The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

The present invention discloses an improved process for the preparation of Imeglimin & salts thereof. More particularly, the present invention discloses chiral resolution of Racemic Imeglimin and its salts which is industrially advantageous and economically significant.

The present invention discloses an improved process for the preparation of Imeglimin & salts thereof. More particularly, the present invention discloses chiral resolution of Racemic Imeglimin and its salts which is industrially advantageous and economically significant.